Document is current
Any future updates will be listed below
-
Authors
Holland, Elizabeth M.
Suryaprakash, Shruthi
Bi, Yu https://orcid.org/0009-0001-6484-2034
Patwardhan, Akshay
Keerthi, Dinesh
Morin, Cara E.
Chan, Sherwin https://orcid.org/0000-0002-2393-8355
Selukar, Subodh
Sharma, Akshay https://orcid.org/0000-0003-3281-2081
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P30CA021765)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R25CA23944)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R25CA23944)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA021765)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R25CA23944)
American Lebanese Syrian Associated Charities
- License Information
-
More Information
Article History
Received: 5 November 2025
Revised: 7 January 2026
Accepted: 25 February 2026
First Online: 17 March 2026
Competing interests
: Akshay Sharma has received consultant fees from Medexus Inc., Vertex Pharmaceuticals, Editas Medicine, BioLineRx, and Gamida-Cell. He is a medical monitor for an RCI BMT clinical trial for which he receives financial compensation. Akshay Sharma is also the St. Jude Children’s Research Hospital site principal investigator for clinical trials of genome editing for sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (NCT03745287), Novartis Pharmaceuticals (NCT04443907), and Beam Therapeutics (NCT05456880). The industry sponsors provide funding for the clinical trials, which includes salary support paid to the investigator’s institution. Akshay Sharma has no direct financial interest in these therapies. These conflicts are managed through the compliance office at St. Jude Children’s Research Hospital in accordance with their conflict-of-interest policy. The other authors have nothing to disclose.
: Study procedures were performed in accordance with the relevant guidelines and regulations. The study was approved by institutional review board (IRB) at St. Jude Children’s Research Hospital (IRB Reference Number: 040351) and was granted an exemption to obtain informed consent from every participant.
